TesoRx Pharma

About TesoRx Pharma

TesoRx Pharma, LLC is a biopharmaceutical company established in 2010 with a focus on developing and commercializing oral drug delivery technology. The company was founded by a team that includes Dr. Guru Betageri, a professor in the College of Pharmacy at Western University of Health Sciences, and Dr. Ramachandran “Ram” Cherlapally. Dr. Betageri's extensive background in drug delivery, with over 30 years of experience and numerous patents, forms the scientific foundation of the company's core technology. Dr. Cherlapally brings both clinical and pharmaceutical industry experience to the venture.

The company's primary business revolves around its proprietary drug delivery platform, which aims to convert existing injectable-only drugs into oral formulations. This technology is designed to improve patient compliance and convenience by eliminating the need for injections. The platform works by protecting the drug from the harsh environment of the stomach and ensuring its release and absorption in the small intestine. TesoRx Pharma operates on a partnership and licensing business model. It collaborates with other pharmaceutical companies to apply its technology to their existing or pipeline drugs, creating new oral versions of established therapies. This approach allows TesoRx to generate revenue through milestone payments and royalties from these partnerships.

A key product in TesoRx's pipeline is TSX-002, an oral testosterone formulation intended for treating male hypogonadism. This product is designed as a once-daily pill, offering a significant advantage over current treatments which are often gels, patches, or injections. The company has engaged in clinical trials to establish the safety and efficacy of its formulations. For instance, it has completed a Phase 1/2 clinical study for its oral testosterone undecanoate formulation. TesoRx's target market includes large pharmaceutical companies seeking to extend the life cycle of their products or develop more patient-friendly drug delivery methods. The company addresses the multi-billion dollar markets for therapies like testosterone replacement and other peptide-based drugs.